58.05 +0.12 (0.20%)
After hours: 4:11PM EST
|Bid||57.55 x 300|
|Ask||59.18 x 200|
|Day's range||57.82 - 58.37|
|52-week range||32.83 - 58.37|
|PE ratio (TTM)||22.73|
|Forward dividend & yield||0.95 (1.71%)|
|1y target est||60.40|
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.
HELSINKI (AP) — Danish drugmaker Novo Nordisk has revised up its offer for Belgian biotech company Ablynx as it looks to find growth opportunities beyond its core business.
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type ...
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.
Danish pharmaceutical company Novo Nordisk A/S offered as much as 2.6 billion euros ($3.1 billion) in cash to acquire Ablynx NV -- its second run at the maker of treatments for rare bleeding disorders ...
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.
We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.
Novo Nordisk’s (NVO) Xultophy (insulin degludec and liraglutide combination) is used as an addition to diet and exercise for improvement of blood sugar levels in adults with type-2 diabetes mellitus whose ...
In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.